# EDGAR Filing Document

**Accession Number:** 0001677940
**File Stem:** 0001171843-26-003344
**Filing Date:** 2026-5
**Character Count:** 17421
**Document Hash:** 1e2880ffd46cd03543bb795f9c71e2a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-003344.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001171843-26-003344

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260513

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BeyondSpring Inc.
- **CENTRAL INDEX KEY:** 0001677940
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38024
- **FILM NUMBER:** 26970864

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR
- **STREET 2:** SUITE 410
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** 646-528-4184

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR
- **STREET 2:** SUITE 410
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

?xml version='1.0' encoding='ASCII'? Form 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

### Washington, D.C. 20549
_________________

### FORM 8-K
_________________

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): May 13, 2026
_______________________________

#### BeyondSpring Inc.
(Exact name of registrant as specified in its charter)

_______________________________

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-38024** | **Not Applicable** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

#### 100 Campus Drive, West Side, 4th Floor, Suite 410

#### Florham Park, New Jersey 07932
(Address of Principal Executive Offices) (Zip Code)

#### +1 (646) 305-6387
(Registrant's telephone number, including area code)

#### Not Applicable
(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Ordinary Shares, par value $0.0001 per share | BYSI | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On May 13, 2026, BeyondSpring Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Exhibit</u>** |
| [99.1](exh_991.htm) | [Press release, dated May 13, 2026.](exh_991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BeyondSpring Inc.** | **BeyondSpring Inc.** |
| Date: May 13, 2026 | By: | <u>/s/ Lan Huang&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  |  | Lan Huang |
|  |  | Chairperson and Chief Executive Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update**

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability

SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy

FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- **BeyondSpring Inc.** (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline.

"Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning as a potential backbone agent across a rapidly evolving treatment landscape," said Dr. Lan Huang, Co-Founder, Chair, and Chief Executive Officer of BeyondSpring. "Data presented at AACR 2026 further highlights the expanding value of our pipeline and reinforces our strategy of advancing highly differentiated therapies with the potential to address significant unmet medical needs. We believe Plinabulin has the potential to become a foundational combination agent that unlocks the full clinical and commercial value of ADC therapies."

Dr. Huang continued, "At SEED, the advancement of ST-01156, a novel RBM39 molecular glue degrader, into clinical development in oncology indications, coupled with a biomarker-driven approach, underscores the strength and scalability of our RITE3™ platform. These milestones reflect disciplined execution across our portfolio and position us to unlock meaningful long-term value through multiple clinical and strategic partnership opportunities."

**Recent Clinical Highlights**

**Plinabulin:** Expanding Role as a Potentially Foundational Combination Therapy

* AACR 2026 data demonstrated that Plinabulin significantly enhances both efficacy and tolerability of topoisomerase inhibitor–based ADC regimens, with or without immune checkpoint inhibitors

* Preclinical findings showed: Improved complete response rate and survival outcomesImproved tolerabilityEnhanced CD8+ T cell / Treg ratio - shifting the tumor immune environment from suppression to attack 

* These preclinical results suggest Plinabulin's potential to address key limitations of current ADC therapies, including limited durability and dose-limiting safety concerns, and support Plinabulin's positioning as a potential backbone agent across a broad range of ADC combination regimens

**SEED Therapeutics:** Advancing precision oncology through molecular glue degraders

* ST-01156 (RBM39 molecular glue degrader) advanced into Phase 1 clinical development, with the first dose cohort completed

* AACR 2026 data demonstrated: Complete tumor eradication in a neuroblastoma in vivo modelIdentification of MYC overexpression and CDKN2A/B deletion as potential predictive biomarkers 

* This program represents a biomarker-driven precision oncology approach and highlights the productivity of SEED's proprietary RITE3™ platform for targeted protein degradation

**First Quarter Financial Results<sup>1</sup>**

Continuing operations:

* R&D expenses were $1.1 million for the three months ended March 31, 2026 compared to $0.9 million for the three months ended March 31, 2025. The $0.2 million increase was primarily driven by increased drug manufacturing activities to prepare for potential future study initiation, partially offset by lower regulatory filing advisory and personnel expenses

* G&A expenses were $1.1 million for the three months ended March 31, 2026 compared to $1.7 million for the three months ended March 31, 2025. The $0.6 million decrease was primarily driven by lower personnel and legal advisory expenses

* Net loss was $2.4 million for the three months ended March 31, 2026 compared to $2.6 million for the three months ended March 31, 2025

* Cash, cash equivalents, and short-term investments were $7.9 million as of March 31, 2026

Discontinued operations:

* Net loss was $4.3 million for the three months ended March 31, 2026, compared to net income of $3.8 million for the three months ended March 31, 2025

* Current assets were $5.3 million as of March 31, 2026

Note 1. As a result of BeyondSpring entering into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED, SEED's operations met the criteria as discontinued operations under ASC 205-20 for financial reporting purposes.

**About BeyondSpring** BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Learn more at beyondspringpharma.com.

**About SEED Therapeutics** SEED Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation. Its proprietary RITE3™ platform is advancing novel molecular glue degraders across oncology, neurodegeneration, and immunology. SEED collaborates with Eli Lilly and Company and Eisai Co., Ltd., and is advancing its RBM39 degrader into clinical development. Learn more at seedtherapeutics.com.

**Investor Contact:** IR@beyondspringpharma.com

**Media Contact:** PR@beyondspringpharma.com

**Cautionary Note Regarding Forward-Looking Statements**

This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge, beliefs, and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all; unexpected results from preclinical studies or clinical trials; the risk that preclinical results may not be predictive of clinical results; delays in, or failure to obtain, regulatory approvals; results that do not meet the Company's expectations regarding the safety, efficacy, clinical utility, or regulatory pathway of the Company's product candidates; increased competition in the market; the Company's ability to meet Nasdaq's continued listing requirements; and other risks described in BeyondSpring's most recent Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release, and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Financial Tables to Follow

---

| | | |
|:---|:---|:---|
| **BEYONDSPRING INC.<br>CONDENSED CONSOLIDATED BALANCE SHEETS<br>(Amounts in thousands of U.S. Dollars ("$"), except for number of shares and per share data)** | **BEYONDSPRING INC.<br>CONDENSED CONSOLIDATED BALANCE SHEETS<br>(Amounts in thousands of U.S. Dollars ("$"), except for number of shares and per share data)** | **BEYONDSPRING INC.<br>CONDENSED CONSOLIDATED BALANCE SHEETS<br>(Amounts in thousands of U.S. Dollars ("$"), except for number of shares and per share data)** |
|  | **As of** | **As of** |
|  | **December 31,<br> 2025** | **March 31,** <br>**2026** |
|  | $ | $ |
|  |  | (Unaudited) |
| **Assets** |  |  |
| **Current assets:** |  |  |
| Cash and cash equivalents |  |  |
| Short-term investments |  |  |
| Advances to suppliers |  |  |
| Prepaid expenses and other current assets |  |  |
| Current assets of discontinued operations |  |  |
| Total current assets |  |  |
| **Noncurrent assets:** |  |  |
| Property and equipment, net |  |  |
| Operating right-of-use assets |  |  |
| Other noncurrent assets |  |  |
| Noncurrent assets of discontinued operations |  |  |
| Total noncurrent assets |  |  |
| **Total assets** |  |  |
| **Liabilities and equity** |  |  |
| **Current liabilities:** |  |  |
| Accounts payable |  |  |
| Accrued expenses |  |  |
| Current portion of operating lease liabilities |  |  |
| Other current liabilities |  |  |
| Current liabilities of discontinued operations |  |  |
| Total current liabilities |  |  |
| **Noncurrent liabilities:** |  |  |
| Deferred revenue |  |  |
| Other noncurrent liabilities |  |  |
| Noncurrent liabilities of discontinued operations |  |  |
| Total noncurrent liabilities |  |  |
| **Total liabilities** |  |  |
| **Shareholders**' **deficit** |  |  |
| Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 41,122,320 and 41,119,820 shares issued and outstanding as of December 31, 2025 and March 31, 2026) |  |  |
| Additional paid-in capital |  |  |
| Accumulated deficit |  |  |
| Accumulated other comprehensive income |  |  |
| Total BeyondSpring Inc.'s shareholders' deficit |  |  |
| Noncontrolling interests |  |  |
| Total shareholders' deficit |  |  |
| **Total liabilities and shareholders**' **deficit** |  |  |

---

---

| | | |
|:---|:---|:---|
| **BEYONDSPRING INC.<br>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)<br>(Amounts in thousands of U.S. Dollars ("$"), except for number of shares and per share data)<br>(Unaudited)** | **BEYONDSPRING INC.<br>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)<br>(Amounts in thousands of U.S. Dollars ("$"), except for number of shares and per share data)<br>(Unaudited)** | **BEYONDSPRING INC.<br>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)<br>(Amounts in thousands of U.S. Dollars ("$"), except for number of shares and per share data)<br>(Unaudited)** |
|  | **Three months ended March 31,** | **Three months ended March 31,** |
|  | **2025** | **2026** |
|  | $ | $ |
| **Revenue** |  |  |
| **Operating expenses** |  |  |
| Research and development |  |  |
| General and administrative |  |  |
| **Loss from operations** |  |  |
| Foreign exchange gain, net |  |  |
| Interest income |  |  |
| Other income, net |  |  |
| **Loss before income tax** |  |  |
| Income tax expenses |  |  |
| **Net loss from continuing operations** |  |  |
| **Discontinued operations** |  |  |
| &nbsp;&nbsp;Loss from discontinued operations |  |  |
| &nbsp;&nbsp;Gain on sale of subsidiary interests |  |  |
| &nbsp;&nbsp;Income tax expenses |  |  |
| **Net income (loss) from discontinued operations** |  |  |
| **Net income (loss)** |  |  |
| Less: Net loss attributable to noncontrolling interests from continuing operations |  |  |
| Less: Net loss attributable to noncontrolling interests from discontinued operations |  |  |
| **Net income (loss) attributable to BeyondSpring Inc.** |  |  |
| **Earnings (loss) per share, basic and diluted** |  |  |
| &nbsp;&nbsp;Continuing operations |  |  |
| &nbsp;&nbsp;Discontinued operations |  |  |
| Basic and diluted earnings (loss) per share |  |  |
| Weighted-average shares outstanding |  |  |
| &nbsp;&nbsp;Basic and diluted |  |  |
| **Other comprehensive loss, net of tax of nil:** |  |  |
| Foreign currency translation adjustment loss from continuing operations |  |  |
| Foreign currency translation adjustment loss from discontinued operations |  |  |
| **Comprehensive income (loss)** |  |  |
| Less: Comprehensive loss attributable to noncontrolling interests from continuing operations |  |  |
| Less: Comprehensive loss attributable to noncontrolling interests from discontinued operations |  |  |
| **Comprehensive income (loss) attributable to BeyondSpring Inc.** |  |  |

---